Gamida Cell Ltd (NASDAQ:GMDA) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,200 shares, a decrease of 84.0% from the December 31st total of 7,500 shares. Based on an average daily trading volume, of 37,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the company’s shares are short sold.
Gamida Cell stock opened at $4.64 on Monday. The firm has a 50 day simple moving average of $4.62 and a 200-day simple moving average of $4.41. Gamida Cell has a 1-year low of $2.93 and a 1-year high of $15.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.61 and a quick ratio of 7.60. The stock has a market cap of $112.39 million, a price-to-earnings ratio of -0.44 and a beta of 1.64.
Gamida Cell (NASDAQ:GMDA) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.07. Equities analysts expect that Gamida Cell will post -1.12 earnings per share for the current fiscal year.
Several research firms have recently weighed in on GMDA. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price target on shares of Gamida Cell in a research note on Tuesday, December 10th. Zacks Investment Research raised shares of Gamida Cell from a “sell” rating to a “hold” rating in a research note on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Gamida Cell presently has an average rating of “Buy” and a consensus target price of $14.25.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Featured Story: Penny Stocks, What You Need To Know
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.